Journal of Hematology and OncologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2

57 records returned

Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pulmonary involvement and skin involvement are rare complications of plasma cell neoplasms. Here we describe what may be the first reported case of a patient with relapse in both of these sites following autologous peripheral blood stem cell transplantation. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - November 13, 2009 Category: Hematology Authors: Yuan YuanRosemary WieczorekDavid GreenPerry CookHarold BallardDavid Araten Source Type: journals

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusi...
Source: Journal of Hematology and Oncology - November 12, 2009 Category: Hematology Authors: David MasielloGerry GorospeAllen Yang Source Type: journals

Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH) : revealing significant overlapping genomic lesions with diffuse large B-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: To the best of our knowledge, the current study represents the first genomic exploration of PL. The genomic aberration pattern of PL appears to be more similar to that of DLBCL (AIDS-related or non AIDS-related) than to PCM. Our findings suggest that PL may remain best classified as a subtype of DLBCL at least at the genome level. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - November 12, 2009 Category: Hematology Authors: Chung-Che ChangXiaobo ZhouJesalyn TaylorWan-Ting HuangXianwen RenFederico MonzonYongdong FengPulivarthi RaoXinYan LuFacchetti FabioSusan HilsenbeckChad CreightonElaine JaffeChing-Ching Lau Source Type: journals

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase positioned at a central point in a variety of cellular signaling cascades. The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer has identified mTOR as a major link in tumorigenesis. Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer. Temsirolimus is an intravenously administered agent approved by the US Food a...
Source: Journal of Hematology and Oncology - October 27, 2009 Category: Hematology Authors: RuiRong YuanAndrea KayWilliam BergDavid Lebwohl Source Type: journals

The transplant iron score as a predictor of stem cell transplant survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Recent studies have suggested that the presence of iron overload prior to stem cell transplantation is associated with decreased survival. Within these studies, the criteria used to define iron overload have varied considerably. Given the lack of consensus regarding the definition of iron overload in the transplant setting, we sought to methodically examine iron status among transplant patients. We studied 78 consecutive patients at risk for transfusion-related iron overload (diagnoses included AML, ALL, MDS, and aplastic anemia) who received either autologous or allogeneic stem cell transplant. Multiple measures of iron s...
Source: Journal of Hematology and Oncology - October 23, 2009 Category: Hematology Authors: Jonathan StoreyRebecca ConnorZachary LewisDavid HurdGregory PomperYi KeungManisha GroverJames LovatoSuzy TortiFrank TortiIstvan Molnar Source Type: journals

Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: a prospective cohort studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Protein C levels were significantly lower in immunocompromised patients when compared to immunocompetent patients in severe sepsis and sepsis categories. Our study suggests a plausible role for APC in severely septic immunocompromised patients which need further elucidation. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 18, 2009 Category: Hematology Authors: Rakshit PanwarBala VenkateshPeter KrugerRobert BirdDevinder GillLeo NunninkGoce Dimeski Source Type: journals

Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a 30-year-old woman with chronic myeloid leukemia who became pregnant twice successfully. Philadelphia-positive CML in its chronic phase was diagnosed at 16 weeks of her first gestation. At that time, she received no treatment throughout her pregnancy. At 38 weeks of gestation, a normal infant was delivered by cesarean section. At six weeks postpartum, the patient underwent imatinib mesylate therapy but she could not tolerate the treatment. The treatment was then changed to nilotinib at 400 mg orally b.i.d. Two years later, she became pregnant again while she was on nilotinib 200 mg b.i.d. The unplanned pregnancy...
Source: Journal of Hematology and Oncology - October 5, 2009 Category: Hematology Authors: Monika ConchonSabri SanabaniIsrael BenditFernanda Maria SantosMariana SerpaPedro Enrique Dorliac-Llacer Source Type: journals

Skeletal Plasmacytoma: Progression of disease and impact of local treatment; an analysis of SEER databaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DiscussionPlasmacytoma consists of two cohorts of patients with different overall survival; those patients that do not progress to systemic disease and those that develop myeloma. Age > 60 years is associated with disease progression. Identifying patients with systemic disease early in the treatment will permit aggressive and novel treatment strategies to be implemented. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - September 23, 2009 Category: Hematology Authors: Muhammad JawadSean Scully Source Type: journals

Complications of Evans' syndrome in an infant with hereditary spherocytosis: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hereditary spherocytosis (HS) is a genetic disorder of the red blood cell membrane that is characterized clinically by anemia, jaundice and splenomegaly. Evans' syndrome is a clinical syndrome characterized by autoimmune hemolytic anemia (AIHA) accompanied by immune thrombocytopenic purpura (ITP). It results from a malfunction of the immune system that produces multiple autoantibodies specific for red blood cells and platelets (and sometimes other targets). Thus, HS and Evans' syndrome differ in their pathophysiological mechanisms. Here, we report the unusual case of an infant who had both of these diseases concurrently. P...
Source: Journal of Hematology and Oncology - September 9, 2009 Category: Hematology Authors: Hideki YoshidaHiroyuki IshidaTakao YoshiharaToyomi KamesakiMasataka KuwanaToshihiko ImamuraAkira Morimoto Source Type: journals

Lymphomatoid granulomatosis masquerading as interstitial pneumonia in a 66-year-old man: a case report and review of literatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of rapid respiratory deterioration in a 66-year-old man with clinical presentation, chest radiography, pulmonary function testing and high resolution computed tomography (HRCT) findings consistent with idiopathic interstitial pneumonia, but very poor response to antibiotics and steroids. Lung biopsy showed histopathology consistent with LG that was confirmed by a positive in situ hybridization for Epstein - Barr virus encoded RNA (EBER). The patient was treated with rituximab and combination chemotherapy and showed significant initial clinical improvement with gradual resolution of abnormal findings on ima...
Source: Journal of Hematology and Oncology - September 3, 2009 Category: Hematology Authors: Ashima MakolKalyan KosuriDeimante TamkusWanderley CalacaHoward Chang Source Type: journals

Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Garcinol, harvested from Garcinia indica, has traditionally been used in tropical regions and appreciated for centuries; however its biological properties are only beginning to be elucidated. There is ample data to suggest potent antioxidant properties of this compound which have been used to explain most of its observed biological activities. However, emerging evidence suggests that garcinol could be useful as an anti-cancer agent, and it is increasingly being realized that garcinol is a pleiotropic agent capable of modulating key regulatory cell signaling pathways. Here we have summarized the progress of our current rese...
Source: Journal of Hematology and Oncology - September 1, 2009 Category: Hematology Authors: Subhash PadhyeAamir AhmadNikhil OswalFazlul Sarkar Source Type: journals

Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Our results highlight the potential prognostic significance of selective high abundance serum APPs in patients with EOCa. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 26, 2009 Category: Hematology Authors: Yeng ChenBoon-Kiong LimOnn Hashim Source Type: journals

Mechanism of action of lenalidomide in hematological malignanciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. . Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of t...
Source: Journal of Hematology and Oncology - August 11, 2009 Category: Hematology Authors: Venumadhav KotlaSwati GoelSangeeta NischalChristoph HeuckKumar VivekBhaskar DasAmit Verma Source Type: journals

Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applicationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ex vivo activation and expansion of lymphocytes for adoptive cell therapy has demonstrated great success. To improve safety and therapeutic efficacy, increased antigen specificity and reduced non-specific response of the ex vivo generated immune cells are necessary. Here, using a complete protein-spanning pool of pentadecapeptides of the latent membrane protein 2A (LMP2A) of Epstein-Barr virus (EBV), a weak viral antigen which is associated with EBV lymphoproliferative diseases, we investigated the phenotype and function of immune effector cells generated based on IFN-gamma or CD137 activation marker selection and dendriti...
Source: Journal of Hematology and Oncology - August 5, 2009 Category: Hematology Authors: Shuhong HanYuju HuangYin LiangYuchin HoYichen WangLung-Ji Chang Source Type: journals

Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases.In recent studies, increasing pCR seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy.The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disapp...
Source: Journal of Hematology and Oncology - August 5, 2009 Category: Hematology Authors: Norma MalavasiGiovanni PontiRoberta DepenniFederica BertoliniSandra ZironiGabriele LuppiPier Franco Conte Source Type: journals

A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from ChinaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: HA is a suitable induction regimen for elderly patients with AML, with relatively low toxicity and reasonable response rate. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 29, 2009 Category: Hematology Authors: Jianmin WangShuqing LuJianmin YangXianmin SongLi ChenChongmei HuangJun HouWeiping Zhang Source Type: journals

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedsideEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents.ABT-869, a novel ATP-competitive receptor tyrosine kinase inhibitor is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. ABT-869 showed potent antiproliferative and apoptotic properties in vitro and in animal cancer xenograft models using tumor cell lines that were "addicted" to signaling of kina...
Source: Journal of Hematology and Oncology - July 29, 2009 Category: Hematology Authors: Jianbiao ZhouBoon-Cher GohDaniel AlbertChien-Shing Chen Source Type: journals

Vorinostat in solid and hematologic malignanciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vorinostat (Zolinza(R)), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy o...
Source: Journal of Hematology and Oncology - July 26, 2009 Category: Hematology Authors: David SiegelMohamad HusseinChandra BelaniFrancisco RobertEvanthia GalanisVictoria RichonJose Garcia-VargasCesar Sanz-RodriguezSyed Rizvi Source Type: journals

Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Female CML patients at LAC+USC Medical Center present with more significant adverse pre-treatment prognostic factors compared to men, but achieve comparable outcomes. Hispanic patients present with lower risk profile CML and achieve better treatment responses compared to non-Hispanic patients as a whole; these ethnic differences are no longer significant when statistical analysis is limited to patients given imatinib as first-line therapy. Our patients achieve response rates inferior to those of large-scale national studies. This constellation of findings has not been reported in previous studies, and is likel...
Source: Journal of Hematology and Oncology - July 23, 2009 Category: Hematology Authors: Justin LeeElliott BirnsteinDavid MasielloDongyun YangAllen Yang Source Type: journals

Update in the management of chronic lymphocytic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete response (CR) rates and progression free survival (PFS). Despite these advances, CLL remains incurable with standard therapies. Thus, there remains a need for more effective therapies in both the upfront and relapsed setting, particularly for patients with high-risk cytogenetic abnormalities such as del(11q22) and del(17p13). The 2008 American Society of Hematology (ASH) Annual Meeting featured several presentations which highlighted the ongoing clinical advances in CLL. The benefit of adding rituxima...
Source: Journal of Hematology and Oncology - July 19, 2009 Category: Hematology Authors: Kami MaddocksThomas Lin Source Type: journals

RIZ1 is potential CML tumor suppressor that is down-regulated during disease progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: RIZ1 is a candidate tumor suppressor gene whose expression is decreased in blast crisis. Loss of RIZ1 activity results in decreased apoptosis and differentiation and enhanced proliferation. Together these results suggest that loss of RIZ1 expression will lead to an increase in myeloid blast cell population resulting in CML progression. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 13, 2009 Category: Hematology Authors: Ashakumary LakshmikuttyammaNaoto TakahashiElodie PasturalEmina TorlakovicHesham AminGuillermo Garcia-ManeroMichael VoraliaMagdalena CzaderJohn DeCoteauC Ronald Geyer Source Type: journals

Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We here report a case of rheumatoid arthritis (RA) with acute myeloid leukemia with multilineage dysplasia (AML-MLD) and Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD). A 64-year-old healthy man suffered from arthralgia, and was ultimately diagnosed with RA based on bilateral hand X-rays showing mild swelling and destruction of the MP and PIP joints. Since non-steroidal anti-inflammatory drugs were not effective, prednisolone and bucillamine were administered. After 4 months, his pancytopenia gradually progressed, and bone marrow (BM) examination revealed the presence of AML-MLD. A chemothe...
Source: Journal of Hematology and Oncology - June 29, 2009 Category: Hematology Authors: Michihide TokuhiraKyoko HanzawaReiko WatanabeYasunobu SekiguchiTomoe NemotoYasuo ToyozumiJun-ichi TamaruShinji ItoyamaKatsuya SuzukiHideto KamedaShigehisa MoriMasahiro Kizaki Source Type: journals

Adult B lymphoblastic leukaemia / lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe a rare presentation of acute lymphoblastic leukemia in a young adult male who had vague and minimal symptoms with mild splenomegaly. There was severe eosinophilia along with absence of blasts in the peripheral blood, and 40% blasts with increase in eosinophils in the bone marrow. The blasts were positive for common precursor B cell markers on flow cytometry. The patient had a unique cytogenetic abnormality t(7;12)(q22;p13),-9, not previously described in acute lymphoblastic leukemia. He was categorized as poor risk due to failure to achieve complete remission after induction with UK ALL XII chemotherapy. (Sourc...
Source: Journal of Hematology and Oncology - June 20, 2009 Category: Hematology Authors: Farhat Abbas BhattiIftikhar HussainMuhammad Zafar Ali Source Type: journals

The effects of beta-glucan on human immune and cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Non-prescriptional use of medicinal herbs among cancer patients is common around the world. The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in vitro or in vivo animal experiments. The current information suggests that these herbal extracts exert their biological effect either through cytotoxic or immunomodulatory mechanisms. One of the active compounds responsible for the immune effects of herbal products is in the form of complex polysaccharides known as beta-glucans. beta-glucans are ubiquitously found in both bacterial or fungal cell walls and have been implicated in the ...
Source: Journal of Hematology and Oncology - June 10, 2009 Category: Hematology Authors: Godfrey Chi-Fung ChanWing Keung ChanDaniel Man-Yuen Sze Source Type: journals

Identification of circulating tumour cells in early stage breast cancer patients using multi-marker immunobead RT-PCREmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Multi-marker immunobead RT-PCR analysis of peripheral blood is a robust assay that is capable of detecting circulating tumour cells in early stage breast cancer patients. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 5, 2009 Category: Hematology Authors: Michael RaynorSally-Anne StephensonKenneth PittmanDavid WalshMichael HendersonAlexander Dobrovic Source Type: journals

Molecular prognostic markers for adult acute myeloid leukemia with normal cytogeneticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately sixty percent of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques. This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allo...
Source: Journal of Hematology and Oncology - June 2, 2009 Category: Hematology Authors: Tara GregoryDavid WaldYichu ChenJohanna VermaatYin XiongWilliam Tse Source Type: journals

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 1, 2009 Category: Hematology Authors: Shundong CangYuehua MaDelong Liu Source Type: journals

Temozolomide and cisplatin in relapsed/refractory acute leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1-5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m2/d times 7 days and cisplatin 100 mg/m2 on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts....
Source: Journal of Hematology and Oncology - May 22, 2009 Category: Hematology Authors: Karen SeiterSreedhar KatragaddaDoris PonceMuhammad RasulNasir Ahmed Source Type: journals

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Phase 2 studies of ezatiostat hydrochloride liposomes for injection in MDS are supported by the tolerability and HI responses observed. An oral formulation of ezatiostat hydrochloride tablets is also in phase 2 clinical development. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 13, 2009 Category: Hematology Authors: Azra Raza, Naomi Galli, Natalie Callander, Leonel Ochoa, Lawrence Piro, Peter Emanuel, Stephanie Willimas, Howard Burris, Stefan Faderl, Zeev Estrov, Peter Curtin, Richard A Larson, James G. Keck, Marsha Jones, Lisa Meng and Gail L. Brown Source Type: journals

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple my...
Source: Journal of Hematology and Oncology - April 28, 2009 Category: Hematology Authors: Zhen-gang Yuan, Xiao-yi Dun, Yong-hua Li and Jian Hou Source Type: journals

Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will discuss targeted therapies for CRC based on EGFR signaling pathway and review published data about the potential usefulness of KRAS as a biological marker for response to these therapies. Results from relevant studies published since 2005 and unpublished results presented at national meetings were retrieved and summarized. These studi...
Source: Journal of Hematology and Oncology - April 22, 2009 Category: Hematology Authors: David Z Chang, Vikas Kumar, Ying Ma, Kuiyuan Li and Scott Kopetz Source Type: journals

Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, quantitative serum Hp levels were shown to be related to cGVHD development. Further, the data suggest the possibility that specific Hp polymorphisms may be associated with cGVHD development and warrant further investigation. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 20, 2009 Category: Hematology Authors: Joseph McGuirk, Gang Hao, Weijian Hou, Sunil Abhyankar, Casey Williams, Weisi Yan, Jianda Yuan, Xiuqin Guan, Robert Belt, Shaun Dejarnette, Jeffery Wieman and Ying Yan Source Type: journals

Treatment of malignant tumors of the skull base with multi-session radiosurgeryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Our experience suggests that multi-session radiosurgery for the treatment of malignant skull base tumors is comparable to other radiosurgical techniques in progression-free survival, local tumor control, and adverse effects. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 2, 2009 Category: Hematology Authors: Nicholas D. Coppa, Daniel M. S. Raper, Ying Zhang, Brian T. Collins, K. WILLIAM Harter, Gregory J. Gagnon, Sean P. Collins and Walter C. Jean Source Type: journals

Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Human beta-globin disorders are relatively common genetic diseases cause by mutations in the beta-globin gene. Increasing the expression of the gamma-globin gene has great benefits in reducing complications associated with these diseases. The Oct-1 transcription factor is involved in the transcriptional regulation of the gamma-globin gene. The human gamma-globin genes (both A-gamma and G-gamma-globin genes) carry three Oct-1 transcription factor consensus sequences within their promoter regions. We have studied the possibility of inducing gamma-globin gene expression using decoy oligonucleotides that target the Oct-1 trans...
Source: Journal of Hematology and Oncology - March 27, 2009 Category: Hematology Authors: Xiaoxin S Xu, Xin Hong and Gan Wang Source Type: journals

R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Both R-CHOP and R-CVP protocols achieve excellent overall response. In patients with known cardiac history, omission of anthracyclines is reasonable and R-CVP provides a competitive CR rate. In younger patients with FL where cumulative cardio-toxicity may be of importance in the long term and in whom future stem cell transplantation is an option, again R-CVP may be a more appealing option. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 24, 2009 Category: Hematology Authors: Siddhartha Ganguly and Vijay Patel Source Type: journals

Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine. Only bilirubin and CA 19-9 levels were predictive of longer survival in this population. Further analysis of potential prognostic and predictive markers of response to treatment and survival are needed. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 16, 2009 Category: Hematology Authors: Bernardo H.L. Goulart, Jeffrey W. Clark, Gregory Y. Lauwers, David P. Ryan, Nina Grenon, Alona Muzikansky and Andrew X. Zhu Source Type: journals

An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Our case illustrates an unusual presentation of hematological malignancies as cholestatic jaundice. It also indicates the non-specific nature of CA 19-9 for pancreaticobiliary malignancies. It is the first case report of neoplastic precursor T cell lymphoblasts with unusual expression of synaptophysin. Tissue biopsy with thorough immunohistochemistry is required to differentiate precursor T-ALL/T-LBL from thymoma and small cell carcinoma. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 12, 2009 Category: Hematology Authors: Kevin J. Patel, Sahibzada U. Latif and Wanderley DE M. Calaca Source Type: journals

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical OncologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologic...
Source: Journal of Hematology and Oncology - February 23, 2009 Category: Hematology Authors: Milind Javle and Chung-Tsen Hsueh Source Type: journals

Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical OncologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We have reviewed the pivotal presentations related to colorectal cancer (CRC) and other gastrointestinal malignancy from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (...
Source: Journal of Hematology and Oncology - February 23, 2009 Category: Hematology Authors: Milind Javle and Chung-Tsen Hsueh Source Type: journals

New dosing schedules of dasatinib for CML and adverse event managementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Resistance to imatinib in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has emerged as a significant clinical issue. Dasatinib is a tyrosine kinase inhibitor that has 325-fold greater in vitro activity against native BCR-ABL (breakpoint cluster region-Abelson leukemia virus) compared with imatinib and can overcome primary (intrinsic) and secondary (acquired) imatinib resistance. Here, we review the clinical profile of dasatinib in imatinib-resistant and -intolerant patients and share clinical approaches for managing adverse events (AEs) to ensure...
Source: Journal of Hematology and Oncology - February 23, 2009 Category: Hematology Authors: Siu-Fun Wong Source Type: journals

Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant miceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Radiation induced earlier and greater temporal changes in multiple cytokines in the pulmonary fibrosis sensitive mice. Positive correlation between blood and tissue levels suggests that blood may be used as a surrogate marker for tissue. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - February 2, 2009 Category: Hematology Authors: Xiaoping Ao, Lujun Zhao, Mary A Davis, David M Lubman, Theodore S Lawrence and Feng-Ming Kong Source Type: journals

Heat-Shock Proteins in Infection-mediated Inflammation-induced TumorigenesisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammation is a necessary albeit insufficient component of tumorigenesis in some cancers. Infectious agents directly implicated in tumorigenesis have been shown to induce inflammation. This process involves both the innate and adaptive components of the immune system which contribute to tumor angiogenesis, tumor tolerance and metastatic properties of neoplasms. Recently, heat-shock proteins have been identified as mediators of this inflammatory process and thus may provide a link between infection-mediated inflammation and subsequent cancer development. In this review, the role of heat-shock proteins in infection-induced...
Source: Journal of Hematology and Oncology - January 30, 2009 Category: Hematology Authors: Mark G Goldstein and Zihai Li Source Type: journals

SET-NUP214 fusion in Acute Myeloid Leukemia- and T-cell Acute Lymphoblastic Leukemia- derived cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Cell lines LOUCY and MEGAL express the recently described SET-NUP214 fusion gene. Of special note is that the formation of the SET exon 7 / NUP214 exon 18 gene transcript requires alternative splicing as the SET breakpoint is located downstream of the stop codon in exon 8. The cell lines are promising model systems for SET-NUP214 studies and should facilitate investigating cellular functions of the the SET-NUP214 protein. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 23, 2009 Category: Hematology Authors: Hilmar Quentmeier, Bjorn Schneider, Sonja Rohrs, Julia Romani, Margarete Zaborski, Roderick AF MacLeod and Hans G Drexler Source Type: journals

Current status of haploidentical stem cell transplantation for leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Haploidentical hematopoietic stem cell transplantation has made tremendous progress over the past 20 years and has become a feasible option for leukemia patients without a HLA identical sibling donor. The early complications of severe graft-versus-host disease (GVHD), graft failure and delayed engraftment, as well as disease recurrence have limited the use of this approach. Newer strategies have been applied and overcome some of the problems, including the use of T-cell depleted graft, "mega" dose of stem cells, intensive post-transplant immunosuppression and manipulation of the graft. These have decreased the transplant r...
Source: Journal of Hematology and Oncology - December 31, 2008 Category: Hematology Authors: Xiao-jun Huang Source Type: journals

Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Concurrent hemolysis in patients with vitamin B12 deficiency is a well-recognized phenomenon and has been attributed to intramedullary destruction of erythrocytes (ineffective erythropoiesis). Recent studies revealed that homocysteine increased the risk of hemolysis in vitamin B12 deficiency in vitro and there is a high frequency (30%) of vitamin B12 deficiency in asymptomatic patients with homozygous methylene tetrahydrofolate reductase (MTHFR) C677T mutation, a known cause of hyperhomocysteinemia. Here we report three patients with MTHFR mutations and vitamin B12 deficiency presenting with hemolytic anemia and severely e...
Source: Journal of Hematology and Oncology - December 18, 2008 Category: Hematology Authors: Utkarsh Acharya, Jen-Tzer Gau, William Horvath, Paolo Ventura, Chung-Tsen Hsueh and Wayne Carlsen Source Type: journals

Treatment of stage I seminoma: is it time to change your practice?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
At the plenary session of the 2008 annual meeting of the American Society of Clinical Oncology, updated results were presented from a large randomized phase III trial comparing adjuvant radiation therapy (RT) and one cycle of Carboplatin for the adjuvant treatment of Stage I seminoma. Results of this Medical Research Council (MRC) trial led its investigators to conclude that one cycle of carboplatin was equivalent in safety and efficacy and less toxic than RT. In this editorial, the trial's design, statistics, toxicity, and length of follow-up are discussed within the context of historical treatments of this disease. With ...
Source: Journal of Hematology and Oncology - November 7, 2008 Category: Hematology Authors: Darren R Feldman and George J Bosl Source Type: journals

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 29, 2008 Category: Hematology Authors: Andrea Molckovsky and Lillian L Siu Source Type: journals

Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: For most patients, the presence of TEL-AML1 fusion gene at diagnosis suggests a favorable prognosis. The present study suggests that persistence of TEL-AML1 fusion as MRD has no additive prognostic value. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 17, 2008 Category: Hematology Authors: Eman Mosad, Hosny B Hamed, Rania M Bakry, Azza M Ezz-Eldin and Nesrine M Khalifa Source Type: journals

P-Loop Mutations and Novel Therapeutic Approaches for Imatinib Failures in Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a substantial number of patients are either initially refractory or develop resistance. Point mutations within the ABL kinase domain of the BCR-ABL fusion protein are a major underlying cause of resistance. Of the known imatinib-resistant mutations, the most frequently occurring involve the ATP-binding loop (P-loop). In vitro evidence has suggested that these mutations are more oncogenic with respect to other mutations and wild type BCR-ABL. Das...
Source: Journal of Hematology and Oncology - October 1, 2008 Category: Hematology Authors: Shundong Cang and Delong Liu Source Type: journals

Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The results of this study show for the first time that arginase II produced by RCC cell lines depletes L-arginine resulting in decreased expression of CD3zeta. These results indicate that RCC cell lines expressing arginase II can modulate the L-arginine metabolic pathway to regulate both cell growth and T-cell function. Blocking arginase may lead to a decrease in RCC cell growth and aid in restoring immune function by increasing L-arginine availability for T-cell use. Understanding the interplay between arginase II and its interaction with the immune system may provide future therapeutic benefits to treat pati...
Source: Journal of Hematology and Oncology - September 25, 2008 Category: Hematology Authors: David J Tate, Derek J Vonderhaar, Yupanqui A Caldas, Toye Metoyer, John R Patterson, Diego H Aviles and Arnold H Zea Source Type: journals